DNA-PK inhibitor, M3814, as a radiation sensitizer in the treatment of neuroendocrine tumors

被引：0
|
作者：
Rychahou, Piotr [1 ]
Chauhan, Aman [2 ,3 ]
Chow, Zeta [1 ]
Izumi, Tadahidi [4 ]
Chen, Quan [5 ]
Lee, Eun Y. [6 ]
Napier, Dana [6 ]
Anthony, Lowell B. [2 ,3 ]
Cavnar, Michael J. [1 ]
Kunos, Charles [7 ]
Evers, B. Mark [1 ,3 ]
机构：
[1] Univ Kentucky, Dept Surg, Lexington, KY USA
[2] Univ Kentucky, Dept Internal Med Med Oncol, Lexington, KY USA
[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[4] Univ Kentucky, Markey Canc Ctr, Dept Toxicol & Canc Biol, Lexington, KY USA
[5] Univ Kentucky, Dept Radiat Med, Lexington, KY USA
[6] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA
[7] NIH, Washington, DC USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6402
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6402
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
    Mark T. J. van Bussel
    Ahmad Awada
    Maja J. A. de Jonge
    Morten Mau-Sørensen
    Dorte Nielsen
    Patrick Schöffski
    Henk M. W. Verheul
    Barbara Sarholz
    Karin Berghoff
    Samer El Bawab
    Mirjam Kuipers
    Lars Damstrup
    Ivan Diaz-Padilla
    Jan H. M. Schellens
    British Journal of Cancer, 2021, 124 : 728 - 735
  • [42] A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
    van Bussel, Mark T. J.
    Awada, Ahmad
    de Jonge, Maja J. A.
    Mau-Sorensen, Morten
    Nielsen, Dorte
    Schoffski, Patrick
    Verheul, Henk M. W.
    Sarholz, Barbara
    Berghoff, Karin
    El Bawab, Samer
    Kuipers, Mirjam
    Damstrup, Lars
    Diaz-Padilla, Ivan
    Schellens, Jan H. M.
    BRITISH JOURNAL OF CANCER, 2021, 124 (04) : 728 - 735
  • [43] Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma
    O'Reilly, E.
    Vormoor, B.
    Kyle, S.
    Newell, H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 88 - 89
  • [44] DNA-PK inhibition releases PARP inhibitor-induced DNA replication stress
    Sunada, Shigeaki
    Miki, Yoshio
    CANCER SCIENCE, 2018, 109 : 833 - 833
  • [45] Activation of DNA-PK by Ionizing Radiation Is Mediated by Protein Phosphatase 6
    Mi, Jun
    Dziegielewski, Jaroslaw
    Bolesta, Elzbieta
    Brautigan, David L.
    Larner, James M.
    PLOS ONE, 2009, 4 (02):
  • [46] Preclinical data of a novel DNA-PK inhibitor in combination with radiation therapy shows promise in the treatment of established GBM and lung carcinoma cell lines
    Mladek, Ann C.
    Burgenske, Danielle L.
    Elmquist, William F.
    Zhong, Wei
    Sarkaria, Jann N.
    CANCER RESEARCH, 2024, 84 (06)
  • [47] Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation
    Soubeyrand, S
    Pope, L
    Pakuts, B
    Haché, RJG
    CANCER RESEARCH, 2003, 63 (06) : 1198 - 1201
  • [48] DNA-PK activation by ionizing radiation-induced DNA single-strand breaks
    Plumb, MA
    Smith, GCM
    Cunniffe, SMT
    Jackson, SP
    O'Neill, P
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1999, 75 (05) : 553 - 561
  • [49] DNA-PK activity plays a role on radioadaptation for radiation-induced apoptosis
    Ohnishi, T
    Takahashi, A
    Ohnishi, K
    RADIATION AND HOMEOSTASIS, PROCEEDINGS, 2002, 1236 : 265 - 270
  • [50] DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors
    Wang, Taixiang
    Kyle, Alastair H.
    Baker, Jennifer H. E.
    Liu, Nannan A.
    Banath, Judit P.
    Teymori, Sevin
    Minchinton, Andrew I.
    DNA REPAIR, 2024, 139
12345